Search

Your search keyword '"Mesenbrink, Peter"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Mesenbrink, Peter" Remove constraint Author: "Mesenbrink, Peter"
209 results on '"Mesenbrink, Peter"'

Search Results

3. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints

4. CohortPlat: Simulation of cohort platform trials investigating combination therapies

5. On model-based time trend adjustments in platform trials with non-concurrent controls

6. Pseudo-domains in imaging data improve prediction of future disease status in multi-center studies

7. Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials

8. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

10. Platform Trial Designs

12. Regulatory Issues of Platform Trials: Learnings from EU‐PEARL

13. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information

15. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

19. Time to onset of antifracture efficacy and year‐by‐year persistence of effect of zoledronic acid in women with osteoporosis

20. Lessons for the setting of an international integrated research platform to conduct adaptive trials in non-alcoholic steatohepatitis: results of the EU-PEARL project

22. Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): an investigation using artificial recurrent neural networks

23. On model-based time trend adjustments in platform trials with non-concurrent controls

24. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.

29. Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials.

30. Incidence of osteonecrosis of the jaw in women with posemenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial

32. Zoledronic acid and clinical fractures and mortality after hip fracture

33. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

34. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease

35. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum

37. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

42. Systematic review of available software for multi-arm multi-stage and platform clinical trial design.

44. Золедроновая кислота в профилактике потери костной ткани у женщин постменопаузального возраста с остеопенией

45. Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture

46. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

47. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture

48. Zoledronic acid and clinical fractures and mortality after hip fracture.

Catalog

Books, media, physical & digital resources